Total Return chart GI Innovation, Inc.

Stocks

End-of-day quote Korea S.E. 2026-09-22			5-day change	1st Jan Change
8,770.00 ^KRW	-6.60%		+4.78%	-50.28%

04-23	GI Innovation Enters Melanoma First-Line Treatment Market with GI-102 Approval for Phase 2 Clinical Trial Direct Comparison with Keytruda	CI
03-20	GI Innovation And Johnson & Johnson Enter Clinical Supply Agreement For Prostate Cancer Combination Therapy	CI

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.